Executive Vice President | Head of Partnering and Transformation Just - Evotec Biologics & Cyprotex | B2B Biotech | VC | Early and Commercial stage | MD | MBA | Scientist by heart
During last Friday’s J.POD opening ceremony in Toulouse, France, I had the opportunity to speak with Richard Saynor, CEO of Sandoz, about the critical role of generics and biosimilars, as well as the potential impact of continuous manufacturing technology on the industry. Some key insights emerged from our discussion: Biosimilars remain not widely accessible, even in developed healthcare systems, highlighting that access challenges aren't limited to developing markets The next decade will see more drugs coming off-patent than the entire history of the generics market, presenting unprecedented opportunities for generics and biosimilars Flexible supply chains and manufacturing will be essential to meet the demands of this dynamic market It was an honor to host the Sandoz team during this milestone event for Just - Evotec Biologics / Evotec, and we look forward to working together to address the critical issue of access
International Business Development Manager at KHAMIS for Medicines and Medical Appliances Trading
2moThanks for sharing !👨⚕️Philip Boehme That's a fantastic summary of your conversation with Richard Saynor! 💬 It's great to hear about the importance of generics and biosimilars, especially in addressing access challenges. 💪 I'm excited to see how continuous manufacturing technology can impact the industry. 🚀 Congratulations on hosting the Sandoz team at the J.POD opening ceremony. Your partnership is a great step towards improving healthcare access. #generics #biosimilars #healthcare #access #innovation